<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Apatinib &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/apatinib/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 16 Dec 2025 04:15:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Apatinib &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Boosting PD-1 Response in Liver Cancer with Apatinib</title>
		<link>https://bioengineer.org/boosting-pd-1-response-in-liver-cancer-with-apatinib/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 16 Dec 2025 04:15:00 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Apatinib]]></category>
		<category><![CDATA[Hepatosellüler karsinom]]></category>
		<category><![CDATA[immünoterapi]]></category>
		<category><![CDATA[PD-1 inhibitörleri]]></category>
		<category><![CDATA[STAT1/NK aksı]]></category>
		<guid isPermaLink="false">https://bioengineer.org/boosting-pd-1-response-in-liver-cancer-with-apatinib/</guid>

					<description><![CDATA[In recent developments in cancer immunotherapy, the combination of Apatinib with PD-1 inhibitors is showing promise for advanced hepatocellular carcinoma (HCC). Research led by an insightful team, including Cui, Wei, and Fu, has unveiled the mechanisms behind this synergistic effect, heralding new avenues for effective cancer treatment. Their landmark study, published in Scientific Reports, focused [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">308214</post-id>	</item>
		<item>
		<title>Apatinib Boosts Osteosarcoma Treatment in Phase II Trial</title>
		<link>https://bioengineer.org/apatinib-boosts-osteosarcoma-treatment-in-phase-ii-trial/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 25 Nov 2025 17:55:37 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[anti-anjiyojenik tedavi]]></category>
		<category><![CDATA[Apatinib]]></category>
		<category><![CDATA[Apatinib kombinasyon tedavisi]]></category>
		<category><![CDATA[faz II klinik çalışma]]></category>
		<category><![CDATA[ilerlemesiz sağkalım]]></category>
		<category><![CDATA[Osteosarcoma Treatment]]></category>
		<category><![CDATA[Osteosarkom tedavisi]]></category>
		<category><![CDATA[phase II clinical trial]]></category>
		<category><![CDATA[VEGFR-2 Inhibitor]]></category>
		<guid isPermaLink="false">https://bioengineer.org/apatinib-boosts-osteosarcoma-treatment-in-phase-ii-trial/</guid>

					<description><![CDATA[In the relentless pursuit of better outcomes for patients diagnosed with advanced osteosarcoma, a groundbreaking clinical investigation has emerged, potentially shifting the therapeutic landscape. The study, recently published in Nature Communications, explores the efficacy of combining Apatinib—a targeted anti-angiogenic agent—with the conventional chemotherapy regimen of ifosfamide and etoposide. This randomized phase II trial, OAIE/PKUPH-sarcoma 11, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">301169</post-id>	</item>
	</channel>
</rss>
